AIM: We investigated candidate genes associated with thiopurine metabolism and clinical response in childhood acute lymphoblastic leukemia. MATERIALS & METHODS: We performed genome-wide SNP association studies of 6-thioguanine and 6-mercaptopurine cytotoxicity using lymphoblastoid cell lines. We then genotyped the top SNPs associated with lymphoblastoid cell line cytotoxicity, together with tagSNPs for genes in the 'thiopurine pathway' (686 total SNPs), in DNA from 589 Caucasian UK ALL97 patients. Functional validation studies were performed by siRNA knockdown in cancer cell lines. RESULTS: SNPs in the thiopurine pathway genes ABCC4, ABCC5, IMPDH1, ITPA, SLC28A3 and XDH, and SNPs located within or near ATP6AP2, FRMD4B, GNG2, KCNMA1 and NME1, were associated with clinical response and measures of thiopurine metabolism. Functional validation showed shifts in cytotoxicity for these genes. CONCLUSION: The clinical response to thiopurines may be regulated by variation in known thiopurine pathway genes and additional novel genes outside of the thiopurine pathway.
RCT Entities:
AIM: We investigated candidate genes associated with thiopurine metabolism and clinical response in childhood acute lymphoblastic leukemia. MATERIALS & METHODS: We performed genome-wide SNP association studies of 6-thioguanine and 6-mercaptopurinecytotoxicity using lymphoblastoid cell lines. We then genotyped the top SNPs associated with lymphoblastoid cell line cytotoxicity, together with tagSNPs for genes in the 'thiopurine pathway' (686 total SNPs), in DNA from 589 Caucasian UK ALL97 patients. Functional validation studies were performed by siRNA knockdown in cancer cell lines. RESULTS: SNPs in the thiopurine pathway genes ABCC4, ABCC5, IMPDH1, ITPA, SLC28A3 and XDH, and SNPs located within or near ATP6AP2, FRMD4B, GNG2, KCNMA1 and NME1, were associated with clinical response and measures of thiopurine metabolism. Functional validation showed shifts in cytotoxicity for these genes. CONCLUSION: The clinical response to thiopurines may be regulated by variation in known thiopurine pathway genes and additional novel genes outside of the thiopurine pathway.
Authors: Lynne Lennard; Sue Richards; Cher S Cartwright; Chris Mitchell; John S Lilleyman; Ajay Vora Journal: Clin Pharmacol Ther Date: 2006-10 Impact factor: 6.875
Authors: D Otterness; C Szumlanski; L Lennard; B Klemetsdal; J Aarbakke; J O Park-Hah; H Iven; K Schmiegelow; E Branum; J O'Brien; R Weinshilboum Journal: Clin Pharmacol Ther Date: 1997-07 Impact factor: 6.875
Authors: R Tamm; R Mägi; R Tremmel; S Winter; E Mihailov; A Smid; A Möricke; K Klein; M Schrappe; M Stanulla; R Houlston; R Weinshilboum; Irena Mlinarič Raščan; A Metspalu; L Milani; M Schwab; E Schaeffeler Journal: Clin Pharmacol Ther Date: 2017-02-01 Impact factor: 6.875
Authors: C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling Journal: Clin Pharmacol Ther Date: 2016-11-18 Impact factor: 6.875
Authors: Raymond L Benza; Mardi Gomberg-Maitland; Teresa Demarco; Adaani E Frost; Adam Torbicki; David Langleben; Tomas Pulido; Priscilla Correa-Jaque; Michael J Passineau; Howard W Wiener; Mayumi Tamari; Tomomitsu Hirota; Michiaki Kubo; Hemant K Tiwari Journal: Am J Respir Crit Care Med Date: 2015-12-01 Impact factor: 21.405
Authors: E W Chua; S Cree; M L Barclay; K Doudney; K Lehnert; A Aitchison; M A Kennedy Journal: Pharmacogenomics J Date: 2015-03-10 Impact factor: 3.550